SCHEMBL136580

SCHEMBL136580

C=COCCOC=C.Cc1cc(CCC(=O)O)c(O)c(C(C)(C)C)c1.Cc1cc(CCC(=O)O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 1/20 0.48
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
HIF1A Q16665 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP2D6 P10635 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CA2 P00918 1/20 0.41
TYR P14679 1/20 0.41
NPSR1 Q6W5P4 1/20 0.38
GPR55 Q9Y2T6 1/20 0.36
VCAM1 P19320 4/20 0.36
GAA P10253 2/20 0.35
SLC6A3 Q01959 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
GLRA3 O75311 1/20 0.34
GLRB P48167 1/20 0.34
GPR17 Q13304 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29368017 1.00 HSPA5 (0.48) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
Ethylene SCHEMBL29161316 0.87 HSPA5 (0.58) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL29504926 0.87 HSPA5 (0.62) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL3440651 0.87 HSPA5 (0.62) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
Ethylene SCHEMBL30473077 0.82 HSPA5 (0.53) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
Triethylene Glycol SCHEMBL466561 0.81 HSPA5 (0.49) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL30019216 0.81 NR1H4 (0.43) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL2918891 0.81 GAA (0.44) CYP2C9CYP2C19HIF1ASMN1; SMN2CYP2D6
SCHEMBL29663822 0.81 GAA (0.44) CYP2C9CYP2C19HIF1ASMN1; SMN2CYP2D6
Propionic Acid SCHEMBL30390758 0.78 GAA (0.42) CYP2C9CYP2C19HIF1ASMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3990534-B1 MIXED ESTER TEREPHTHALATE COMPOSITIONS USEFUL AS PLASTICIZERS EASTMAN CHEM CO (US) 2025-12-10 EP claimed
US-12378389-B2 Mixed ester terephthalate compositions useful as plasticizers EASTMAN CHEMICAL COMPANY (US) 2025-08-05 US claimed
US-20220315737-A1 MIXED ESTER TEREPHTHALATE COMPOSITIONS USEFUL AS PLASTICIZERS EASTMAN CHEMICAL COMPANY (US) 2022-10-06 US claimed
US-20220306835-A1 METHOD FOR PREPARING POLYISOCYANATE COMPOSITION Hanwha Solutions Corporation (KR) 2022-09-29 US claimed
EP-4019564-A1 METHOD FOR PRODUCING POLYISOCYANATE COMPOSITION Hanwha Solutions Corporation (KR) 2022-06-29 EP claimed
EP-3990534-A1 MIXED ESTER TEREPHTHALATE COMPOSITIONS USEFUL AS PLASTICIZERS Eastman Chemical Company (US) 2022-05-04 EP claimed
EP-3787892-A1 MASS COLORED POLYMER COMPOSITION FOR USE IN MEDICAL TECHNOLOGY APPLICATIONS Celanese Sales Germany GmbH (DE) 2021-03-10 EP claimed
WO-2020263594-A1 MIXED ESTER TEREPHTHALATE COMPOSITIONS USEFUL AS PLASTICIZERS EASTMAN CHEMICAL COMPANY (US) 2020-12-30 WO claimed
US-20200115524-A1 CITRATE ESTER-POLYVINYL CHLORIDE COMPOSITIONS AND THEIR USE AS HEAT STABLE INSULATORS EASTMAN CHEMICAL COMPANY (US) 2020-04-16 US claimed
US-20190338116-A1 Mass Colored Polymer Composition For Use In Medical Technology Applications CELANESE SALES GERMANY GMBH (DE) 2019-11-07 US claimed
WO-2026090534-A1 SULFONATED POLYPHENYLENE MEMBRANES COMPRISING ANTIOXIDANTS AND METHODS OF USE THEREOF IONOMR INNOVATIONS INC. (CA) 2026-04-30 WO disclosed
US-20260099051-A1 INJECTION MOLDED LIGHT-GUIDING MEMBER AND HEAD-MOUNTED DISPLAY ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-04-09 US disclosed
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses TOKUYAMA CORPORATION (JP) 2026-04-07 US disclosed
EP-4715011-A1 THERMOPLASTIC RESIN COMPOSITION PRODUCTION METHOD AND THERMOPLASTIC RESIN COMPOSITION MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-03-25 EP disclosed
US-20260071030-A1 THERMOPLASTIC RESIN, MOLDED BODY CONTAINING THERMOPLASTIC RESIN, AND OPTICAL LENS MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-03-12 US disclosed
US-20120055693-A1 KIT FOR PREPARING WATER-SEALING MATERIAL FOR ELECTRICAL WIRE, WATER-SEALING MATERIAL FOR ELECTRICAL WIRE, WATER-SEALING MEMBER, WATER-SEALED ELECTRICAL WIRE, AND WATER-SEALING METHOD JSR CORPORATION (JP) 2012-03-08 US disclosed
US-7851585-B2 Polyacetal compositions with improved tribological properties E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-14 US disclosed
EP-2201065-A1 POLYACETAL COMPOSITIONS WITH IMPROVED TRIBOLOGICAL PROPERTIES E. I. du Pont de Nemours and Company (US) 2010-06-30 EP disclosed
WO-2009052161-A1 POLYACETAL COMPOSITIONS WITH IMPROVED TRIBOLOGICAL PROPERTIES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-04-23 WO disclosed
US-20090105426-A1 Polyacetal compositions with improved tribological properties DELRIN USA, LLC 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260099051-A1 INJECTION MOLDED LIGHT-GUIDING MEMBER AND HEAD-MOUNTED DISPLAY NR2E3, STRA6, UACA HSPA5 3264/4885CYP2C9 2711/4885CYP2C19 1638/4885
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses CRYAA, CRYZ, CRY2 HSPA5 3025/4885CYP2C9 1179/4885CYP2C19 2136/4885
US-20260071030-A1 THERMOPLASTIC RESIN, MOLDED BODY CONTAINING THERMOPLASTIC RESIN, AND OPTICAL LENS DERL1, WDR1, RIF1 HSPA5 1009/4885CYP2C9 3040/4885CYP2C19 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.